The American Society of Hematology has highlighted the need for the training of physicians and scientists, basic and clinical research, in hematology. The training program in hematology at the University of Minnesota addresses this concern by providing: 1) inter- and multi-disciplinary research training in five major realms of hematology;2 senior and junior faculty members of both genders as mentors;3) a fusion of research and clinical training for physician and PhD trainees;4) an outstanding resource-filled environment;and 5) the skills for trainees to both survive and thrive in academic medicine. The overarching objective of the training program is to train physicians and scientists for careers in academic medicine and hematology related research. Our program philosophy is to achieve this by carefully balancing sufficient structure to ensure rigor of the trainee experience and programmatic flexibility to accommodate the different needs of trainees. It is our intention to provide trainees with the basic skills that are adaptable to new paradigms of disease, capable of embracing of new technologies, and committed to the highest ethical standards. This post-doctoral training program will allow six trainees at least two years of research experience. This hematology training program, in the tradition of the last 35 years, is confident that future leader of hematology research will matriculate through the University of Minnesota program.
Advanced research training of doctors and scientists focused on blood diseases is essential to finding cures for leukemia or the prevention of fatal blood clots. This training program will prepare hematologists and scientists to develop new scientifically-based treatments and understandings of these diseases to improve the health and safety of patients will blood diseases.
|Baumann Kreuziger, L M; Morton, C T; Subramanian, A T et al. (2014) Not only in trauma patients: hospital-wide implementation of a massive transfusion protocol. Transfus Med 24:162-8|
|Foley, Bree; Felices, Martin; Cichocki, Frank et al. (2014) The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev 258:45-63|
|Felices, Martin; Lenvik, Todd R; Ankarlo, Dave E M et al. (2014) Functional NK cell repertoires are maintained through IL-2R? and Fas ligand. J Immunol 192:3889-97|
|Fujioka, Naomi; Ainslie-Waldman, Cheryl E; Upadhyaya, Pramod et al. (2014) Urinary 3,3'-diindolylmethane: a biomarker of glucobrassicin exposure and indole-3-carbinol uptake in humans. Cancer Epidemiol Biomarkers Prev 23:282-7|
|Baumann Kreuziger, Lisa M; Tarchand, Gobind; Morrison, Vicki A (2014) The impact of Agent Orange exposure on presentation and prognosis of patients with chronic lymphocytic leukemia. Leuk Lymphoma 55:63-6|
|Patel, Manish R; Jacobson, Blake A; Belgum, Holly et al. (2014) Measles vaccine strains for virotherapy of non-small-cell lung carcinoma. J Thorac Oncol 9:1101-10|
|Felices, Martin; Ankarlo, Dave E M; Lenvik, Todd R et al. (2014) Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation. J Immunol 193:3344-54|
|Ermakova, Elena; Miller, Michelle C; Nesmelova, Irina V et al. (2013) Lactose binding to human galectin-7 (p53-induced gene 1) induces long-range effects through the protein resulting in increased dimer stability and evidence for positive cooperativity. Glycobiology 23:508-23|
|Patel, Manish R; Jay-Dixon, Joe; Sadiq, Ahad A et al. (2013) Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC. J Thorac Oncol 8:1142-7|
|Zylla, Dylan; Gourley, Brett L; Vang, Derek et al. (2013) Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 119:4103-10|
Showing the most recent 10 out of 46 publications